We are live on ! Find out more
PRQR icon

ProQR Therapeutics

77 hedge funds and large institutions have $118M invested in ProQR Therapeutics in 2024 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 17 increasing their positions, 6 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

388% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 8

271% more capital invested

Capital invested by funds: $31.7M → $118M (+$86M)

183% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 6

82% more call options, than puts

Call options by funds: $296K | Put options by funds: $163K

64% more funds holding

Funds holding: 4777 (+30)

21.69% more ownership

Funds ownership: 21.36%43.05% (+22%)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

Holders
77
Holders Change
+30
Holders Change %
+63.83%
% of All Funds
1.01%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
39
Increased
17
Reduced
6
Closed
8
Calls
$296K
Puts
$163K
Net Calls
+$133K
Net Calls Change
-$678K

PRQR Hedge Fund Activity: Q4 2024 in Review

77 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q4 2024, worth a combined $118M — up 271% from $31.7M a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new PRQR positions and 8 closed out — a net gain of 31 holders — while 17 added to existing stakes and 6 trimmed.

The largest buyer was Adage Capital Partners, adding an estimated $19M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $3.34M sold.

  • 77 institutional investors held ProQR Therapeutics (PRQR) as of Q4 2024, up from 47 in Q3 2024.
  • Funds reported $118M of ProQR Therapeutics stock for Q4 2024, up 271% quarter-over-quarter.
  • 39 funds opened new ProQR Therapeutics positions in Q4 2024 and 8 closed out, a net change of +31 holders.
  • The largest ProQR Therapeutics buyer in Q4 2024 was Adage Capital Partners, an estimated $19M added.
  • The largest ProQR Therapeutics seller in Q4 2024 was EcoR1 Capital, an estimated $3.34M sold.

Based on aggregated 13F filings for Q4 2024.